Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Other financing activities (2021 - 2025)

Nuvectis Pharma has reported Other financing activities over the past 5 years, most recently at $82000.0 for Q4 2025.

  • Quarterly results put Other financing activities at $82000.0 for Q4 2025, down 33.87% from a year ago — trailing twelve months through Dec 2025 was $548000.0 (up 43.46% YoY), and the annual figure for FY2025 was $548000.0, up 43.46%.
  • Other financing activities reached $82000.0 in Q4 2025 per NVCT's latest filing, up from -$1.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $1.6 million in Q2 2021 and bottomed at -$1.2 million in Q2 2023.
  • Median Other financing activities over the past 5 years was $130000.0 (2021), compared with a mean of $177333.3.
  • The largest annual shift saw Other financing activities surged 875.0% in 2024 before it tumbled 2272.0% in 2025.
  • Over 5 years, Other financing activities stood at $136000.0 in 2021, then plummeted by 720.59% to -$844000.0 in 2022, then surged by 98.1% to -$16000.0 in 2023, then soared by 875.0% to $124000.0 in 2024, then crashed by 33.87% to $82000.0 in 2025.
  • Business Quant data shows Other financing activities for NVCT at $82000.0 in Q4 2025, -$1.1 million in Q3 2025, and $300000.0 in Q2 2025.